Influence of eugenol on the pharmacokinetics and pharmacodynamics of gliclazide in rabbits

Diabetes is the most prevailing health disorder with high mortality rate and showing increased health costs across the globe. World Health Organization has claimed that lifestyle changes are one of the major causes of diabetes in this modern living. Gliclazide is an oral antidiabetic drug that is taken by majority of patients suffering with type-2 diabetes. With the increased awareness of nutraceuticals in health care management, many patients are consuming them. Hence, in the present investigation it is sought to determine the pharmacokinetic and pharmacodynamic interactions of gliclazide with eugenol in diabetic induced rabbits. Streptozotocin was used for inducing diabetes in healthy rabbits. Four different groups, each with 6 rabbits, are taken in the study. Group A is diabetic control, Group B is treated with gliclazide alone, Group C is treated with eugenol alone and Group D is treated with combination of gliclazide and eugenol. The results clearly indicated that there is an advantage in both pharmacokinetic and pharmacodynamic parameters with combination therapy of gliclazide and eugenol in diabetic rabbits.